Polyrizon Engages Leading Branding Firm for Strategic Brand Development
Polyrizon (Nasdaq: PLRZ) has partnered with a leading global branding and trademark consultancy firm to develop strategic branding for its Capture and Contain™ (C&C) hydrogel technology. The collaboration aims to create brand identity for their innovative intranasal spray formulation, which creates a protective biological barrier against allergens and viruses.
The engagement includes comprehensive trademark screening and linguistic evaluations across U.S. and European markets to ensure brand viability and regulatory compliance. The brand development process is scheduled to align with Polyrizon's ongoing clinical and regulatory milestones.
Polyrizon (Nasdaq: PLRZ) ha collaborato con una rinomata azienda globale di branding e consulenza sui marchi per sviluppare un branding strategico per la sua tecnologia Capture and Contain™ (C&C) idrogel. La collaborazione ha l'obiettivo di creare un'identità di marca per la loro innovativa formulazione di spray intranasale, che crea una barriera biologica protettiva contro allergeni e virus.
L'impegno include un'analisi completa dei marchi e valutazioni linguistiche nei mercati statunitensi ed europei per garantire la fattibilità del marchio e la conformità normativa. Il processo di sviluppo del marchio è programmato per allinearsi con le attuali tappe cliniche e normative di Polyrizon.
Polyrizon (Nasdaq: PLRZ) se ha asociado con una destacada firma global de consultoría de marcas y propiedad intelectual para desarrollar un branding estratégico para su tecnología de hidrogel Capture and Contain™ (C&C). La colaboración tiene como objetivo crear una identidad de marca para su innovadora formulación de spray intranasal, que crea una barrera biológica protectora contra alérgenos y virus.
El compromiso incluye un exhaustivo análisis de marcas y evaluaciones lingüísticas en los mercados de EE. UU. y Europa para asegurar la viabilidad de la marca y el cumplimiento normativo. El proceso de desarrollo de la marca está programado para alinearse con los hitos clínicos y regulatorios en curso de Polyrizon.
Polyrizon (Nasdaq: PLRZ)는 세계적인 브랜드 및 상표 컨설팅 회사와 협력하여 Capture and Contain™ (C&C) 하이드로겔 기술을 위한 전략적 브랜딩을 개발하고 있습니다. 이 협력은 알레르기 유발 물질과 바이러스에 대한 보호 생물학적 장벽을 형성하는 혁신적인 비강 스프레이 제형의 브랜드 아이덴티티를 만드는 것을 목표로 합니다.
이 참여에는 미국 및 유럽 시장에서의 포괄적인 상표 스크리닝과 언어 평가가 포함되어 있어 브랜드의 실행 가능성과 규제 준수를 보장합니다. 브랜드 개발 과정은 Polyrizon의 현재 임상 및 규제 이정표와 일치하도록 예정되어 있습니다.
Polyrizon (Nasdaq: PLRZ) s'est associé à une entreprise de conseil en branding et en marques de renommée mondiale pour développer une stratégie de branding pour sa technologie de hydrogel Capture and Contain™ (C&C). Cette collaboration vise à créer une identité de marque pour leur formulation innovante de spray intranasal, qui crée une barrière biologique protectrice contre les allergènes et les virus.
L'engagement comprend un dépistage complet des marques et des évaluations linguistiques sur les marchés américain et européen afin d'assurer la viabilité de la marque et la conformité réglementaire. Le processus de développement de la marque est prévu pour s'aligner sur les jalons cliniques et réglementaires en cours de Polyrizon.
Polyrizon (Nasdaq: PLRZ) hat sich mit einer führenden globalen Branding- und Markenberatungsfirma zusammengeschlossen, um strategisches Branding für seine Capture and Contain™ (C&C) Hydrogel-Technologie zu entwickeln. Die Zusammenarbeit zielt darauf ab, eine Markenidentität für ihre innovative intranasale Sprühformulierung zu schaffen, die eine schützende biologische Barriere gegen Allergene und Viren bildet.
Das Engagement umfasst umfassende Markenprüfungen und sprachliche Bewertungen in den US-amerikanischen und europäischen Märkten, um die Markenviabilität und die Einhaltung der Vorschriften sicherzustellen. Der Prozess der Markenentwicklung ist so geplant, dass er mit den laufenden klinischen und regulatorischen Meilensteinen von Polyrizon in Einklang steht.
- Strategic preparation for product commercialization
- Engagement with globally recognized branding firm indicates serious market entry plans
- None.
Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide.
Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel technology, an innovative intranasal spray formulation designed to create a protective biological barrier against allergens and viruses. This initiative marks a crucial step forward in Polyrizon's pathway to commercialize its technology and effectively communicate its unique benefits to the market.
The scope of the engagement will encompass comprehensive trademark screening and linguistic evaluations across the U.S. and European markets, ensuring optimal brand viability and compliance with global regulatory requirements.
Polyrizon anticipates completing the brand development process in alignment with its ongoing clinical and regulatory milestones.
About Polyrizon Ltd.
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its pathway to commercialize its technology and effectively communicate its unique benefits to the market and its anticipation of completing the brand development process in alignment with its ongoing clinical and regulatory milestones. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contact: IR@polyrizon-biotech.com
FAQ
What is the purpose of Polyrizon's (PLRZ) new branding partnership announced in April 2025?
What is Polyrizon's (PLRZ) Capture and Contain™ technology designed to do?
Which markets will Polyrizon's (PLRZ) branding initiative target?
When will Polyrizon (PLRZ) complete its brand development process?
